Previous Article | Next Article ![]()
Journal of Bacteriology, October 2005, p. 7090-7102, Vol. 187, No. 20
0021-9193/05/$08.00+0 doi:10.1128/JB.187.20.7090-7102.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Department of Microbiology, University of Chicago, Chicago, Illinois 60637
Received 4 May 2005/ Accepted 2 August 2005
|
|
|---|
|
|
|---|
Type III secretion of gram-negative pathogens is unique in that the type III machinery transports polypeptides through a narrow needle complex spanning 50 to 100 nm while crossing the bacterial double-membrane envelope and the plasma membrane of host target cells (54, 67). Unlike secretion machines for signal peptide-bearing precursors, the type III pathway fulfills accessory roles and is not needed for bacterial growth under laboratory conditions (7, 51). However, as bacteria encounter immune cells during infection, type III secretion becomes essential in preventing phagocytic killing of the invading microbes (50, 65, 66). The expression of genes encoding type III machines and their substrates is regulated in all bacterial species, and there is increasing evidence not only that each microbial species employs unique sets of genes encoding type III effector proteins for host cell injection but also that the order in which these polypeptides are transported is developmentally determined (1, 32, 39, 59).
Pathogenic yersiniae, Yersinia enterocolitica, Y. pseudotuberculosis, and Y. pestis, depend on the type III secretion system encoded by their respective 70-kb virulence plasmids to transport Yops during host infection (23). When these bacteria are incubated with cultured tissue cells, several type III substrates (effectors) are injected into the eukaryotic cytosol (YopE, YopH, YopM, YopN, YopO, YopP, YopT, YscM1, and YscM2) (22). Moreover, four proteins are also secreted by the type III pathway into the extracellular medium (LcrV, YopB, YopD, and YopR) (42, 44). Yersinia can be induced for type III secretion even without host target cells, as depletion of calcium ions at elevated temperatures causes secretion of Yops into the culture medium (52). Massive induction of type III secretion is associated with a reduction in growth (41). This "low-calcium response" (LCR) phenomenon has been exploited for the identification of genes involved in promoting or regulating type III secretion (33). Because the concentration of free calcium ions in the eukaryotic cytosol is well below the threshold for the in vitro induction of Yop secretion, the low-calcium signal is thought to serve as a physiological inducer for the type III pathway during infection (43).
Fusions of ubiquitin to YopE or YopQ generated hybrids that cannot be transported by the type III pathway (45). This phenotype is caused by reporter assembly into its three-dimensional structure, as mutations that destabilize the ubiquitin fold generate hybrid polypeptides capable of traveling through the needle complex (45). Fusions of dihydrofolate reductase to YopE or YopQ are also not transported by the type III machinery. Moreover, a fusion of full-length YopE to DHFR blocked secretion of Yops, consistent with the canonical view that DHFR hybrids jam the type III secretion machinery (30).
We show here that YopE-DHFR and YopE-LacZ block the Yersinia type III pathway as well as the injection of Yops into host cells. The type III blockade of YopE-DHFR appears to be caused by the reduced expression of yop genes, not by the inhibition of secretion. Consistent with this view, YopE-DHFR blocked the LCR phenotype of Y. pestis and mutations in genes (yopD, lcrH, yscM1 [lcrQ], and yscM2) encoding proteins that function as posttranscriptional repressors of the type III pathway restored Yop secretion. Furthermore, mutations in Y. enterocolitica yscM1 and yscM2 also restored type III injection of host cells even in the presence of YopE-DHFR. Taken together with the observation that YopE-DHFR is not successfully initiated into the secretion pathway, these data suggest a model whereby rejection of YopE-DHFR from secretion machines can inhibit type III gene expression.
|
|
|---|
yopN), MC2
lcrG), VTL2 (
yopD), CT133 (
lcrH), and EC2 [
(yscM1 yscM2)] have been described previously (3, 16, 44, 46). Escherichia coli DH5
(35) was grown in Luria broth in the presence of either 35 µg/ml kanamycin or 20 µg/ml chloramphenicol. Y. pestis MEL2 (
lcrQ) was constructed by introducing a stop codon followed by a +1 frameshift mutation after codon 6 in Y. pestis KIM D27 using allelic exchange as described previously (18). Briefly, the suicide pLC28 vector was digested with SalI and PstI. Two fragments of lcrQ were amplified using primers lcrQKO-SalI (5'-AAGTCGACCAATGGAACCCCAACCTCAGGC-3') and lcrQKO-Eco1 (5'-AAGAATTCTTCAAAGAGTATTGATTTTCATCGAG-3') as well as lcrQKO-Eco2 (5'-AAGAATTCCAATCGTTAATAAATCAACAAATTACCC-3') and lcrQKO-PstI (5'-AACTGCAGCGAAAGTTAAGCTTCAGTAAGCG-3'). The resulting fragments were cloned into pCR2.1 (Invitrogen) and then subcloned into pLC28 (18) using a three-way ligation to yield pMM54. pMM54 was transformed directly into Y. pestis KIM D27 and selected on blood base agar (BBA) containing chloramphenicol. The resulting chloramphenicol-resistant colonies were cured of the insert and drug resistance marker by streaking on BBA containing 5% sucrose. Colonies were screened by PCR using primers lcrQKO-SalI and lcrQKO-PstI to amplify lcrQ. The PCR products were digested with EcoRI to screen for the introduction of the EcoRI restriction site.
Molecular biology experiments.
The plasmid pBBR1MCS-2 (38) was used to clone the yopE-dhfr and yopE-lacZ fusions. In order to facilitate cloning, two restriction sites were eliminated (XbaI and BglII). Plasmid pBBR1MCS-2 was digested with BglII, purified, end filled with the Klenow enzyme (New England Biolabs), ligated, and transformed into E. coli DH5
. Plasmid DNA was purified from the resulting colonies and analyzed for the loss of the BglII restriction site by digestion with BglII (pJS91). Elimination of the XbaI restriction site was performed in the same manner using pJS91 to yield pJS92. The yopE-dhfr fusion was cloned from the plasmid pMAF35 (30) into pJS92 by restriction digestion (EcoRI-HindIII) and ligation to yield pJS93. The ß-galactosidase gene was PCR amplified from pDA14 (pyopE-lacZ) using the forward primer 5'LacZ-BglII (5'-AAAGATCTATGACTATGATTACGGATTCT-3') and the reverse primer 3'LacZ-XbaI (5'-AATCTAGATTATTTTTGACACCAGACCAA-3'). The PCR product was digested with BglII and XbaI and cloned into pJS93 precut with BglII and XbaI to yield pJS94. The tac promoter and lacIq gene were cloned into pJS93 from pDA38 (5) using EcoRI-NdeI restriction digestion and ligation to yield pJS95.
Type III secretion assay. Overnight cultures of Y. pestis KIM8 were diluted 1:50 into fresh M9-Casamino Acids medium (M9-Ca) (42 mM Na2HPO4, 22 mM KH2PO4, 8.6 mM NaCl, 18.6 mM NH4Cl, 0.01 mg/ml FeSO4, 0.001% thiamine, 1 mM MgSO4, 0.4% glucose, and 1% Casamino Acids) containing an antibiotic for plasmid retention. Overnight cultures of Y. enterocolitica W22703 pVL20 (pyopE-dhfr; low copy number) were diluted 1:50 into TSB as described previously (45). Overnight cultures of Y. enterocolitica W22703(pJS93) were diluted 1:50 into brain heart infusion broth (BHI) containing 4 mg/ml glucose. To chelate calcium from BHI and TSB, 20 mM oxalic acid and 20 mM magnesium chloride were added to the media as a supplement. In some cases, 5 mM CaCl2 was added to the media to block type III secretion. Cultures were grown for 2 h at 26°C and then at 37°C for 3 h to induce type III secretion. A 1.4-ml aliquot of culture was removed and centrifuged at 16,000 x g to sediment the bacteria. Seventy-five microliters of 100% trichloroacetic acid (TCA) was added to 1 ml of culture supernatant. Seven hundred microliters of water was added to the bacterial pellet, and 500 µl of the bacterial suspension was precipitated with 500 µl 10% TCA. Precipitated samples were acetone washed, dried, and solubilized in sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer. Protein samples were separated by 15% SDS-PAGE and stained with Coomassie brilliant blue or electrotransferred to polyvinylidene difluoride (PVDF) membranes. Following electrotransfer, proteins were immunoblotted using specific antisera raised against individual Yop proteins and neomycin phosphotransferase (NPT). Horseradish peroxidase-conjugated anti-rabbit secondary antibody and chemiluminescence were used to visualize the samples. Images were quantified using a Fluorchem 8800 imaging system (Alpha Innotech).
Tissue culture infections.
HeLa cells (ATCC CCL-2) were grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2 mM glutamine at 37°C and 5% CO2. Two hours prior to infection, the overnight yersinia culture was diluted 1:20 in fresh heart infusion broth (Y. pestis) or fresh TSB (Y. enterocolitica) with an antibiotic in two separate tubes. Ten minutes prior to infection, IPTG (isopropyl-ß-D-thiogalactopyranoside) was added to a final concentration of 1 mM in one of the two tubes to induce expression of yopE-dhfr. One hour prior to infection, 80 to 90% confluent HeLa cell monolayers were washed twice with phosphate-buffered saline (PBS) and 10 ml DMEM without FBS/glutamine was added. HeLa cells were infected with Y. pestis KIM8 or Y. enterocolitica W22703 transformed with pJS95 at a multiplicity of infection of 10 in the presence of the antibiotic and 1 mM IPTG where indicated in Fig. 4 and 9. After 3 h, the medium fraction was decanted and centrifuged at 10,000 x g for 15 min. Protein in 7 ml of media supernatant was precipitated with methanol-chloroform, and the remaining medium sample was discarded. Ten milliliters of PBS containing 1% SDS was added to the medium pellet, and protein in 7 ml of this sample was precipitated with methanol-chloroform. To the adherent tissue culture cells and their attached bacteria, 1% digitonin in PBS was added to disperse the host cell plasma membrane followed by incubation on a rotary shaker for 20 min (D). Cell remnants and bacteria were detached from the flasks using a cell scraper, and samples were centrifuged and protein was precipitated as described above. Samples were separated by 15% SDS-PAGE and electrotransferred to PVDF membranes. Following electrotransfer, proteins were immunoblotted using specific antisera raised against individual Yop proteins, NPT, chloramphenicol acetyltransferase, and I
B. Horseradish peroxidase-conjugated anti-rabbit secondary antibody and chemiluminescence were used to visualize the samples.
![]() View larger version (28K): [in a new window] |
FIG. 4. YopE-DHFR blocks Y. pestis type III injection into HeLa cells. (A) Y. pestis strain KIM8(pJS95) was inoculated into HeLa cell monolayers for 3 h at 37°C. Infected tissue cultures were fractionated as described in Materials and Methods, and protein localization was analyzed by immunoblotting with specific antisera. M, medium fraction; D, digitonin fraction; S, supernatant fraction; P, pellet fraction; , anti. (B) Data in panel A were analyzed to determine the percent amount of injected polypeptide. The bars indicate the means of three independent experiments. The error bars indicate 1 standard deviation of the mean. Significance was calculated using Student's t test (*, P < 0.01; **, P < 0.05). (C) Y. pestis cytotoxicity for HeLa cells was measured by staining F-actin with Texas red-conjugated phalloidin. Differential interference contrast (DIC) images were captured at a magnification of x600, and fluorescence was measured at 608-nm emission. Samples were compared with a slide that received no bacteria (uninfected). (D) Model for YopE-DHFR-mediated block of type III injection.
|
![]() View larger version (42K): [in a new window] |
FIG. 9. YopE-DHFR cannot block type III injection of class II mutant Y. enterocolitica. (A) Strain EC2 [ (yscM1 yscM2)] carrying pJS93 was analyzed for type III injection into HeLa cells as described in the legend to Fig. 4. , anti. (B) Data in panel A were analyzed to determine the percent amount of injected polypeptide. (C) Y. enterocolitica cytotoxicity for HeLa cells was measured by fluorescence microscopy and Texas red-phalloidin staining.
|
RNA isolation and RT-PCR analysis. Total RNA from Y. enterocolitica W22703(pJS95), uninduced or IPTG induced for type III secretion as described above, was isolated using an RNeasy minikit (QIAGEN) by following the manufacturer's instructions. DNA was removed by incubating with TURBO DNase (Ambion), and RNA was repurified by phenol extraction and ethanol precipitation. For reverse transcriptase PCR (RT-PCR) analysis, 300 ng of total RNA was used to synthesize cDNA of yopB, lcrV, and rpoA using the primers 3'YopB (5'-ATGGGGTCTGCCGGCCAAATTA-3'), 3'LcrV (5'-TCATATTTCTGAATGAAACGGTTCAGTGCTTCA-3'), and 3'RpoA (5'-TCTAGGCGCATGCCTAAAGAAAGACCA-3'). Primers were annealed to RNA by incubation at 65°C for 5 min and then placed on ice for 5 min. Cloned avian myeloblastosis virus reverse transcriptase (Invitrogen) was added together with 0.5 mM deoxynucleoside triphosphates and incubated at 42°C for 60 min. The reaction was stopped by incubation at 95°C for 5 min, and then the reaction mixture was placed on ice. The resulting cDNA was used as a template for PCR amplification using primer sets 5'YopB (5'-GCATCAAAGATTTTTGGCTGGCTCA-3') and 3'YopB, 5'LcrV (5'-ATGATTAGAGCCTACGAACAAAACCCACAAC-3') and 3'LcrV, and 5'RpoA (5'-ATGCAGGGTTCTGTGACAGAGTTTCT-3') and 3'RpoA. The resulting PCR product was separated by electrophoresis on 0.8% agarose gel.
Pulse-labeling of Y. enterocolitica and immunoprecipitation.
Overnight cultures of Y. enterocolitica W22703(pJS95) and EC2(pJS95) [
(yscM1 yscM2)] were grown in M9-Ca medium supplemented with an antibiotic for plasmid retention. Cultures were diluted into two separate tubes that contained M9-Ca lacking methionine and cysteine (18) and grown for 2 h at 26°C. IPTG was added to one of the tubes to a concentration of 1 mM. An 800-µl aliquot of each culture was labeled with 8 µCi of Pro-Mix for 2 min at 37°C. Three 250-µl aliquots were precipitated with 250 µl ice-cold 10% TCA and then acetone washed. Precipitated samples were suspended in SDS-sample buffer and immunoprecipitated with specific YopB, LcrV, or RpoA antibodies. Immunoprecipitated samples were solubilized in SDS-sample buffer, separated by 15% SDS-PAGE, and quantified by PhosphorImager.
|
|
|---|
![]() View larger version (35K): [in a new window] |
FIG. 1. Effect of low-copy-number (pVL20) and medium-copy-number (pMAF35) plasmids carrying yopE-dhfr on type III secretion of Y. enterocolitica W22703. Type III secretion was measured by separating the medium supernatant (S) and the bacterial pellet (P) of centrifuged cultures that had been induced by temperature shift and low calcium (+ or ). (A) Proteins in both fractions were separated by SDS-PAGE and stained with Coomassie brilliant blue. The positions of molecular weight markers are indicated. (B) Proteins were also electroblotted onto a PVDF membrane and detected with specific antisera. , anti.
|
![]() View larger version (53K): [in a new window] |
FIG. 2. Plasmids carrying yopE-dhfr (pJS93) or yopE-lacZ (pJS94), but not the vector control (pJS92), block type III secretion of Y. pestis KIM8. (A) Coomassie brilliant blue-stained, SDS-PAGE-separated proteins in the Yersinia medium supernatant (S) and the bacterial pellet (P). (B) Immunoblot analysis of protein localization in the medium supernatant and the bacterial pellet. , anti. (C) Quantification of immunoblot analysis in panel B for the percent amount of secreted protein and comparison between bacteria harboring pJS92 (vector control) and pJS93 (yopE-dhfr). Bars represent the means of three independent experiments. The error bars represent the standard errors of the means. Significance was determined using Student's t test. (D) Total amounts of Yersinia proteins were determined by immunoblotting of proteins from whole-culture samples and compared between bacteria expressing YopE-DHFR (pJS93) and the vector control (pJS92).
|
Our experimental design cannot distinguish between defects in substrate recognition, for example, rejection of proteins from entering the type III secretion pathway, and defects in transport, for example, obstruction of the pathway by proteins that are too bulky for the narrow needle complex. yopE-dhfr expression hindered the secretion of only four proteins, and it would therefore seem unlikely that the YopE-DHFR hybrid would obstruct the needle complex, as this would be expected to precipitate a general blockade in type III secretion. Secretion, i.e., the sum of substrate recognition and transport events, was also measured in Y. enterocolitica (Fig. 1B). Expression of yopE-dhfr did not affect substrate recognition and transport of YopE and YopH; however, that of LcrV, YopB, YopD, and YopJ was reduced (Fig. 1B). Thus, yopE-dhfr expression seems to exert similar effects on substrate secretion in different Yersinia species. Importantly, yopE-dhfr expression also did not impose a general block of the Y. enterocolitica type III machinery. When cells were induced in the absence of calcium, the overall abundance of YopE-DHFR was 18% of that of YopE (data not shown).
YopE-DHFR reduces the expression of yop genes. Close inspection of immunoblots in Fig. 1 and 2 revealed that the overall amount of Yop proteins was reduced in yersiniae expressing yopE-dhfr. To substantiate this hypothesis, we measured the total amount of Yop protein produced in Yersinia cultures by immunoblotting of TCA-precipitated samples. Expression of yopE-dhfr only slightly reduced or left unaffected the production of YopN and LcrQ. However, YopE-DHFR significantly reduced the immune-reactive signals of YopB, YopM, YopQ, YopJ, YopH, YopR, YopD, and LcrV, further corroborating the notion that the hybrid reduced the total amount of a subset of type III substrates (Fig. 2D).
If YopE-DHFR reduced the expression of type III genes, one would expect that the hybrid protein may also affect the LCR of Y. pestis. Removal of calcium ions from agar medium prevents growth and colony formation of Y. pestis (41), and it is now appreciated that massive transport of Yop proteins via the type III pathway hinders bacterial growth under these conditions (52). To test whether expression of yopE-dhfr blocks the LCR, Y. pestis strains carrying pJS92 or pJS95, a plasmid expressing yopE-dhfr from the IPTG-inducible tac promoter (2), were streaked on agar media lacking calcium (Fig. 3). In the presence of calcium, Y. pestis KIM8(pJS92) and Y. pestis KIM8(pJS95) both formed colonies. However, when streaked on agar medium lacking calcium, neither of the two strains multiplied to form colonies. This result indicates that strain KIM8 is subject to LCR suppression of bacterial growth irrespective of the presence or absence of the plasmid. When streaked on calcium-depleted agar medium containing IPTG, Y. pestis KIM8(pJS95), but not Y. pestis KIM8(pJS92), formed colonies. Thus, IPTG-induced expression of yopE-dhfr blocks the LCR of Y. pestis.
![]() View larger version (48K): [in a new window] |
FIG. 3. YopE-DHFR blocks the Y. pestis LCR. Y. pestis strain KIM8 was transformed with a vector control plasmid or with the same vector expressing yopE-dhfr from the IPTG-inducible tac promoter (pJS95). Strains were streaked on HIA plates and incubated at 37°C with or without calcium, the latter of which is an inducer of the type III pathway, and with or without IPTG, an inducer of the tac promoter.
|
B from the HeLa cell cytosol but not NPT from the bacterial cytoplasm. In contrast, after addition of the IPTG inducer, Y. pestis synthesized YopE-DHFR, which abolished all type III injection of YopE and significantly reduced the injection of YopH, YopM, and YopN (Fig. 4A). However, neither the type III injection of YopJ nor the secretion of YopR was significantly reduced (Fig. 4A and B). If YopE-DHFR mediated at least a partial blockade of the type III pathway, as suggested by data in Fig. 4A and B, we would expect to observe defects in Yersinia type III pathway-mediated HeLa cell cytotoxicity (65). To test this prediction, Yersinia-infected tissue culture cells were stained with Texas red-phalloidin and viewed by fluorescence microscopy. Y. pestis strain KIM8 infection of HeLa cultures caused rounding of cells and redistribution of actin filaments (Fig. 4C). In contrast, the YopE-DHFR-mediated blockade of the type III pathway abolished Yop protein cytotoxicity, consistent with the hypothesis that the hybrid blocked Y. pestis injection of Yops (Fig. 4D). To examine whether the YopE-DHFR blockade occurred also in Y. enterocolitica, HeLa tissue culture cells were inoculated with strain W22703(pJS95). Without IPTG induction of yopE-dhfr, Y. enterocolitica injected YopE, YopH, YopM, and YopN, whereas YopR was secreted into the extracellular medium (Fig. 5A). IPTG-induced expression of yopE-dhfr led to the synthesis of YopE-DHFR, which was not transported by the type III machinery but remained in the pellet fraction (Fig. 5A). YopE-DHFR not only blocked all Y. enterocolitica type III injection of YopE, YopH, and YopN but also reduced the injection of YopM and secretion of YopR (Fig. 5A and B).
![]() View larger version (17K): [in a new window] |
FIG. 5. YopE-DHFR blocks Y. enterocolitica type III injection into HeLa cells. (A) Y. enterocolitica strain W22703(pJS95) was inoculated into HeLa cell monolayers for 3 h at 37°C and subjected to digitonin fractionation as described in Materials and Methods. , anti. (B) Data in panel A were analyzed to determine the percent amount of injected polypeptide.
|
yopD) was quantified by immunoblotting. Expression of yopE-dhfr did not affect the secretion of YopE, YopH, YopJ, or YopB in the wild type or the class II mutant strain VTL2. However, the observed increase in the amount of type III secreted proteins occurred through increases in the synthesis of YopE, YopH, YopJ, YopB, and LcrV (Fig. 6C).
![]() View larger version (24K): [in a new window] |
FIG. 6. Mutations in class II genes relieve the type III blockade of YopE-DHFR. Y. enterocolitica W22703(pJS92) (vector control) and strains W22703, VTL1 ( yopN), MC2 ( lcrG), VTL2 ( yopD), CT133 ( lcrH), and EC2 [ (yscM1 yscM2)], each carrying pJS93, were analyzed for type III secretion in the absence of calcium. (A) Coomassie brilliant blue-stained SDS-PAGE gel for separation of proteins in the medium supernatant (S) and the bacterial pellet (P). The positions of molecular weight markers are indicated. (B) Proteins in the supernatant and bacterial pellet fractions were also electroblotted onto a PVDF membrane, analyzed with specific antisera for strains W22703 (wild type) and VTL2 ( yopD), and quantified for the percent amount of secreted polypeptide. (C) Total amounts of Yersinia proteins were determined by immunoblotting proteins from whole-culture samples and compared between bacteria expressing YopE-DHFR (pJS93) and the vector control (pJS92).
|
![]() View larger version (22K): [in a new window] |
FIG. 7. Expression of yopE-dhfr does not affect yop transcript levels but results in an inhibition of Yop protein synthesis. (A) Total RNA was isolated from Y. enterocolitica W22703(pJS95) that had been induced for type III secretion. Where indicated, IPTG was added to the culture to induce the expression of yopE-dhfr. Transcript levels of yopB, lcrV, and rpoA were analyzed by RT-PCR. As a control for cDNA synthesis, reverse transcriptase (RT) was omitted from the reaction where indicated. (B) Y. enterocolitica W22703(pJS95) (black bars) and EC2(pJS95) [ (yscM1 yscM2)] (gray bars) cultures induced for type III secretion were pulse-labeled with 10 µCi/ml Pro-Mix, TCA precipitated, immunoprecipitated, and analyzed by SDS-PAGE and phosphorimaging. Relative amounts of protein synthesis were calculated by dividing the total amount of YopB and LcrV synthesized in strains expressing yopE-dhfr by the total amount of YopB and LcrV synthesized in strains not expressing yopE-dhfr. Values were normalized to the expression of RpoA and multiplied by 100%. Black and gray bars indicate the means of four independent experiments. Error bars indicate 1 standard deviation from the mean. Statistical significance was calculated using Student's t test. *, P < 0.01; **, P < 0.05.
|
(yscM1 yscM2)] were induced for type III secretion in the presence and absence of IPTG. After 3 h of induction an aliquot of culture was removed and newly synthesized proteins were pulse-labeled with 10 µCi/ml of [35S]methionine and [35S]cysteine for 2 min. Equal amounts of culture were TCA precipitated, and proteins were immunoprecipitated and then separated by SDS-PAGE. The amount of synthesized protein was quantified using phosphorimaging, and protein levels were normalized to the non-type III control protein RpoA. The observed rates of synthesis are depicted as ratios of the total amount of synthesis in strains expressing yopE-dhfr versus strains not expressing yopE-dhfr (Fig. 7B). Expression of yopE-dhfr in wild-type Y. enterocolitica led to a significant reduction in the amount of newly synthesized YopB and LcrV (Fig. 7B). Expression of yopE-dhfr in the class II mutant led to a restoration of the rate of YopB and LcrV synthesis (Fig. 7B). Pulse-labeling of YopB and LcrV and a chase of cultures with unlabeled methionine/cysteine permitted analysis of the turnover of immunoprecipitated polypeptides. We did not detect changes in the turnover rates of YopB and LcrV in the presence of yopE-dhfr expression. Together these data suggest that the expression of yopE-dhfr results in an inhibition of Yop protein synthesis and not in a decrease in yop transcription. Further, the observed feedback inhibition in the synthesis of YopB and LcrV was suppressed by a class II regulatory mutant.
Mutations in lcrQ relieve the block of Y. pestis LCR.
Y. pestis expresses lcrQ, a class II gene and posttranscriptional repressor with homology to the functionally redundant yscM1 and yscM2 of Y. enterocolitica (15, 64, 76). To test whether or not the YopE-DHFR-mediated block in the LCR could be overcome by lcrQ mutations, Y. pestis strain MEL2 (
lcrQ) was transformed with pJS95 or with the pJS92 vector control. Transformants were streaked on heart infusion agar (HIA) plates with or without IPTG and incubated at 28 or 37°C for 2 days. Y. pestis strain MEL2 grew at 28°C even in the absence of IPTG and irrespective of the presence or absence of yopE-dhfr (Fig. 8). When the temperature was shifted to 37°C, IPTG induction of yopE-dhfr could not restore growth on agar medium. The addition of calcium to agar media also could not restore the growth of Y. pestis strain MEL2, as class II mutations abolish posttranscriptional repression of yop genes in the presence or absence of environmental calcium ions (16).
![]() View larger version (42K): [in a new window] |
FIG. 8. YopE-DHFR cannot block temperature-sensitive growth of class II mutant Y. pestis. Y. pestis strain MEL2 ( lcrQ) was transformed with a vector control plasmid or with a plasmid expressing yopE-dhfr from the IPTG-inducible tac promoter (pJS95). Strains were streaked on HIA plates and incubated at 28 or 37°C with or without calcium and with or without IPTG, an inducer of the tac promoter driving yopE-dhfr expression.
|
(yscM1 yscM2)] was inoculated into HeLa cell cultures and expression of yopE-dhfr was controlled by the addition or omission of IPTG. In the absence of IPTG, YopE-DHFR was not synthesized and the
(yscM1 yscM2) mutant strain EC2 injected YopE, YopH, YopM, and YopN into HeLa cells and YopR was secreted into the extracellular medium. Upon addition of IPTG, the expression of YopE-DHFR could be detected in bacterial cells. As expected, the hybrid protein was not injected into HeLa cells but instead sedimented with the bacteria into the pellet fraction. However, digitonin fractionation could detect type III injection for YopH, YopM, and YopN and the secretion of YopR. YopE, on the other hand was neither secreted nor injected (Fig. 9B). This result can be explained by the YopE-DHFR-mediated sequestration of SycE, a cytoplasmic chaperone and YopE binding protein that is absolutely required for its type III injection into mammalian cells (20, 73). Restoration of effector Yop injection in the presence of YopE-DHFR could be observed by fluorescence microscopy, as cells displayed rounding and Texas red-phalloidin staining revealed actin redistribution throughout the cytoplasm in both the presence and absence of IPTG (Fig. 9C). Thus,
(yscM1 yscM2) mutations in Y. enterocolitica restore type III injection of effector Yops even in the presence of the impassable substrate YopE-DHFR. Role of sycE in the yopE-dhfr blockade of the type III pathway. Previous work indicated that SycE, a small cytoplasmic chaperone that binds YopE residues 15 to 78 (8, 20, 73, 75), is required for the yopE-dhfr-mediated blockade of type III secretion (30). To test whether overexpression of sycE can rescue YopE-DHFR secretion or relieve the type III blockade, a high-copy-number plasmid carrying sycE (20) was transformed into wild-type and sycE and yscM1 yscM2 mutant strains. As expected, overexpression of sycE resulted in an increase in the total amount of SycE and an increase in the total amount of YopE and YopE-DHFR. The latter is likely due to the stabilization of both wild-type YopE and YopE-DHFR due to increases in the concentration of the SycE chaperone (20). However, overexpression of sycE did not restore the decrease in YopD synthesis in the presence of yopE-dhfr expression (Fig. 10). Previous experiments have shown that expression of yopE-dhfr does not result in a blockade of type III secretion in a sycE mutant background (30). Interestingly, deletion of the sycE gene led to a drastic decrease in the overall concentration of YopE-DHFR (Fig. 10). Pulse-chase analysis with a [35S]methionine-labeled polypeptide revealed that deletion of sycE also caused an increase in the degradation of the YopE-DHFR, similar to wild-type YopE (18) (data not shown). As expected, overexpression of sycE within the yscM1 yscM2 mutant did not affect YopD synthesis (Fig. 10). Taken together, these results confirm the requirement for SycE in the YopE-DHFR-mediated inhibition of synthesis of type III substrates. However, overexpression of sycE does not affect the YopE-DHFR-mediated blockade of the type III pathway.
![]() View larger version (26K): [in a new window] |
FIG. 10. Overexpression of sycE does not rescue the inhibition of Yop synthesis in strains expressing yopE-dhfr. Strains of Y. enterocolitica expressing pJS95 (yopE-dhfr) were transformed with a high-copy-number plasmid that expresses sycE from the native sycE promoter. The resulting strains were induced for type III secretion by chelation of calcium. Cultures were centrifuged to separate medium in the supernatant (S) from bacterial sediment (P, pellet), and proteins were detected by immunoblotting. Where indicated, IPTG was added to the culture to induce the expression of yopE-dhfr. , anti.
|
2-15-dhfr did not affect the secretion of Yop proteins, as measured by Coomassie staining and SDS-PAGE (Fig. 11A). When these samples were analyzed by immunoblotting, it was found that expression of yopE-dhfr leads to a decrease in the amount of YopD synthesized although small amounts of type III transport of this polypeptide still occurred. However, expression of yopE
2-15-dhfr did not affect YopD synthesis or promote a block in type III secretion (Fig. 11B). Together these data suggest that YopE-DHFR initiation into and YopE-DHFR rejection from the type III pathway trigger reduced synthesis of type III secretion substrates.
![]() View larger version (27K): [in a new window] |
FIG. 11. Removal of the YopE secretion signal abolished the YopE-DHFR blockade of the type III pathway. Y. enterocolitica W22703 expressing yopE-dhfr or yopE 2-15-dhfr was induced for low-calcium type III secretion in the presence or the absence of IPTG. Cultures were centrifuged to separate medium in the supernatant (S) from bacterial sediment (P, pellet), and proteins were separated on a 15% SDS-PAGE gel and stained with Coomassie brilliant blue (A) or transferred to a PVDF membrane and immunoblotted with specific YopE, YopD, and NPT antibodies (B). , anti.
|
|
|
|---|
Mapping of secretion signals has shed some light on the unique properties of type III machines. While the first 7 to 12 codons of yop genes include the signals necessary and sufficient for secretion of hybrid proteins generated from fused reporter genes, three arguments question the functionality of classical signal peptides (48, 62, 69). First, bioinformatic analysis failed to reveal a universal feature (amino acid conservation or peptide motif) of Yop proteins that could function as a secretion signal for the type III machine (21). Second, frameshift mutations in yop coding sequences do not abolish the function of secretion signals (4), whereas some synonymous mutations in yop secretion signals can abolish substrate recognition (34, 63). Third, multiple sequence elements of yop genes, in a successive manner beginning at the 5' end (N-terminal end) and including amino acid binding sites for secretion chaperones, contribute to substrate recognition and translocation efficiency in a manner that is unique for each substrate, suggesting that each Yop protein assumes a defined position in a cascade of secretion reactions (18, 61). These observations are not limited to yersiniae. For example, the secretion signal properties of Xanthomonas sp. type III substrates are similar to those of yersiniae (55). Further, export of heterologous proteins by the flagellar basal body complex of Escherichia coli occurs when the 5' untranslated region of the flagellin gene is fused to reporter gene coding sequence (49). Taken together, these results suggest that substrate recognition in type III secretion of gram-negative bacteria involves at least some features of the mRNAs that encode proteins destined to travel the pathway (60, 68).
In this report, we add to the unique features of type III secretion machines. Although the type III machinery cannot transport impassable substrates, as has been shown for the TAT pathway, these hybrids do not jam the pathway and indeed do not even interfere with its function. Because YopE-DHFR is neither inserted into type III needles nor associated with the membrane envelope (45), we conclude that the hybrid polypeptide must be rejected from the type III secretion pathway. To our knowledge, type III secretion is the first example for the rejection of an impassable transport substrate for any membrane translocator. The notion that impassable substrates inhibit gene expression of other substrates, presumably via feedback inhibition loops to prevent cellular accumulation of polypeptides, has been reported for several secretion systems including Sec transport of signal peptide-bearing precursors across the plasma membrane (56, 57). Genetic relief of the YopE-DHFR blockade of type III secretion points to the class II genes, whose products are known to regulate gene expression in the yop virulon by a posttranscriptional mechanism that involves a short nucleotide sequence in yop untranslated regions as a target (16).
The hypothesis that impassable substrates of type III pathways can be rejected provides new insight into the workings of this fascinating translocation machine. The irrevocable fate of Yop proteins does not seem to be initiation into the type III pathway and transport. If it were, substrates such as YopE-DHFR would be continuously initiated and would thereby clog up the machine. However, it appears as if YopE-DHFR molecules that were rejected could no longer be considered substrates by the secretion machine. Such separation of secretion signal-controlled fate and the destiny of mature polypeptides can provide fertile experimental grounds for testing the mRNA signal hypothesis in type III secretion. However, we realize that a myriad of mechanistic possibilities, even those involving polypeptide properties (47), could lead to the permanent rejection of substrate from the pathway, and additional experimentation is needed to study the fate of proteins that are rejected from the type III pathway. Nevertheless, the data presented here provide several new opportunities, namely, to map the signal of yopE or of other yop genes required for implementing feedback inhibition via class II gene repression and the possible identification of yopE elements required for rejection of substrate from the type III pathway.
This work was supported by United States Public Health Awards from the National Institute of Allergy and Infectious Diseases, Infectious Diseases Branch AI42797, to O. Schneewind. J. Sorg acknowledges support from the Molecular Cell Biology Training Grant T32GM007183. M. Marketon and O. Schneewind acknowledge membership within and support from the Region V "Great Lakes" Regional Center of Excellence in Biodefense and Emerging Infectious Diseases Consortium (GLRCE, National Institute of Allergy and Infectious Diseases Award 1-U54-AI-057153).
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»